Abstract：
The ALINA trial1 demonstrated that 2 years of adjuvant alectinib achieved statistically significantly improved 2-year overall and central nervous system (CNS) disease-free survival over platinum-doublet chemotherapy in resected early-stage (IB ≥ 4 cm to IIIA) ALK+ non-small cell lung cancer (NSCLC). Identifying early-stage ALK+ NSCLC patients (60% were never-smokers in the ALINA trial) may require low-dose computed tomography (LDCT) lung cancer screening in never-smokers.
摘要：
ALINA试验1表明，在切除的早期（IB≥4cm至IIIA）ALK非小细胞肺癌（NSCLC）中，与铂双重化疗相比，2年的辅助治疗阿莱替尼在统计学上显着改善了2年的总体和中枢神经系统（CNS）无病生存率。识别早期ALK+NSCLC患者(在ALINA试验中60%是从不吸烟者)可能需要在从不吸烟者中进行低剂量计算机断层扫描(LDCT)肺癌筛查。
